Salute e Benessere

OPTIMUM trial demonstrates value of SKY92 in detecting high-risk myeloma and…

The independent prospective multi-center UK OPTIMUM trial published in the Journal of Clinical Oncology by the UK collaborative trial group, offered patients from nearly 40 hospitals across the UK extended molecular risk screening over standard of care, by combining SKY92 with standard genetic testing for two or more high-risk markers, also termed Ultra high-risk MM (UHRMM). Patients identified as having UHRMM by either marker, or those with plasma cell leukemia (PCL), were offered intensified…
PR Newswire
28/09/2023

Notice to the BBS-Bioactive Bone Substitutes Plc's Extraordinary General Meeting

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 28 September 2023 at 2.20 pm (EET)Notice to the BBS-Bioactive Bone Substitutes Plc's Extraordinary General Meeting The shareholders of BBS-Bioactive Bone Substitutes Plc are invited to the company's Extraordinary General Meeting (EGM), which is held at the company's premises at Kiviharjunlenkki 6, 90220 Oulu, onMonday 23October 2023 starting at 2.00 pm (EET). The right to attend will be on each shareholder who, on the...
Nasdaq GlobeNewswire
28/09/2023

Peptone Expands Leadership Team with Key Executive Hires

"The expansion of Peptone's executive team with deep drug discovery and development expertise comes at an important moment in time for the company and will enable us to capitalize on our proprietary computational and experimental approaches, accelerating the company's internal drug discovery programs and external partnerships," said Kamil Tamiola, PhD, CEO of Peptone. "We are thrilled to welcome Patrik and David to the organization and grateful for Benjamin and Andrew's leadership…
PR Newswire
28/09/2023

STADA and Calliditas announce the filing for full marketing authorization of…

Kinpeygo is the first and only approved treatment in Europe for IgAN, a rare, progressive autoimmune disease of the kidney with a high unmet need. STADA, which holds European commercial rights, already launched the IgAN medicine in Germany in September 2022 and is working to extend patient access to other countries. Kinpeygo is the first and only approved treatment inEuropefor IgAN, a rare, progressive autoimmune disease of the kidney with a high unmet need. STADA, which holds European...
PR Newswire
28/09/2023

Ariceum Therapeutics' targeted radiopharmaceutical 177Lu-satoreotide exhibits…

The Phase I/II trial was initiated by Ipsen, and recently completed after Ariceum acquired satoreotide from Ipsen. This international study was conducted in 7 countries - Australia, Austria, Canada, Denmark, France, Switzerland, and the UK - and enrolled 40 patients with advanced, SSTR2-positive NETs. The primary tumours of the patients included progressive, grade 1 and 2 (≈60%) gastroenteropancreatic (GEP), and (a)typical lung NETs, paraganglioma, and pheochromocytoma. All patients had…
PR Newswire
28/09/2023

NorthX Biologics AB Announces Inauguration of Innovation Hub at Matfors Facility

The Innovation Hub represents NorthX's dedication to pushing the boundaries of biotechnology by fostering collaboration, research, and development in advanced therapies. With a focus on manufacturing of advanced biologics including Vaccine, Cell and Gene therapies, the Innovation Hub is set to become a catalyst for breakthroughs in medical science. This facility supplements NorthX's existing expertise in Plasmid and Protein manufacturing by adding mRNA services, reinforcing the company's...
Nasdaq GlobeNewswire
28/09/2023

Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis

The study was performed on children between 4 months and 3 years of age and aimed at identifying children with Atopic Dermatitis with the use of Nevisense. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to create an Augmented Intelligence (AI) algorithm to identify healthy skin from atopic skin, even when measurements were performed on visually unaffected skin. The top-line results of the study indicated that: The study was performed on children...
PR Newswire
28/09/2023

Mendus will participate in multiple investor and industry conferences in October…

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX Nordic Congress Copenhagen, Denmark, October 10-11, 2023Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present a Company Update at the conference: https://www.lsxleaders.com/lsx-nordic-congress Innate Killer Summit Europe London, UK,...
Nasdaq GlobeNewswire
28/09/2023

Unlock the Secrets of Timeless Beauty and Harness the Power of Icelandic Kelp…

At its core, the Purification Treatment relies on NoTox®, an innovative technology devised by TARAMAR that extracts the potent skin rejuvenating properties of this oceanic wonder. The result is the Arctic Complex®, a proprietary blend that not only preserves but also amplifies the incredible properties of organic kelp, delivering a transformative experience that leaves your complexion radiant and revitalized. At its core, the Purification Treatment relies on NoTox®, an innovative technology...
PR Newswire
28/09/2023

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Jonathan Milner issues Open Letter to shareholders of Abcam plcUrges shareholders to VoteAGAINST the proposed acquisition of Abcam by Danaher CorporationCAMBRIDGE, England, 28 September 2023– Dr. Jonathan Milner, the founder and one of the largest investors in Abcam plc (“Abcam” or the “Company”) (NYSE: ABCM) with ownership of 6.15%, today issued an open letter to the Company's shareholders announcing his “Vote AGAINST” campaign and providing them with the...
Nasdaq GlobeNewswire
28/09/2023

Basilea announces New England Journal of Medicine publication of phase 3 data on…

Allschwil, Switzerland, September 28, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine (NEJM), one of the world's leading peer-reviewed medical journals. 1In the study, Basilea's ceftobiprole, a beta-lactam antibiotic, was evaluated...
Nasdaq GlobeNewswire
28/09/2023

Graft Versus Host Disease Market to Witness Upsurge in Growth During the…

Key Takeaways from the Graft Versus Host Disease Market Report Key Takeaways from the Graft Versus Host Disease Market Report Discover which therapies are expected to grab the major graft versus host disease market share @Graft Versus Host Disease Market Report Graft Versus Host Disease Overview Graft-versus-host disease (GvHD) is a complex and potentially life-threatening condition that can occur after a bone marrow or stem cell transplant. This ailment arises when donor...
PR Newswire
27/09/2023

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR…

thAnnual Meeting (SITC 2023), that will take place on November 1-5, 2023 at San Diego Convention Center in San Diego (CA). Poster Presentation: Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer. Title :TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR...
Nasdaq GlobeNewswire
27/09/2023

EssilorLuxottica: Ray-Ban and Meta launch the next generation of smart glasses

RAY-BAN AND META LAUNCH THE NEXT GENERATION OF SMART GLASSES The new Ray-Ban I Meta smart glasses features Meta AI, advanced audio and camera capabilities, design customization opportunities, and expanded European distributionMenlo Park, California, and Charenton-le-Pont, France (September 27, 2023 – 11:00 am PST)– Meta Platforms, Inc. and EssilorLuxottica introduced their next generation of smart glasses, theRay-Ban Meta smart glasses,today during the annual Meta Connect...
Nasdaq GlobeNewswire
27/09/2023

Calliditas Therapeutics granted orphan drug designation by the FDA for the…

"We are excited to start another clinical program in the renal space targeting an orphan indication where today there are no approved products," said CEO Renée Aguiar-Lucander. "We are excited to start another clinical program in the renal space targeting an orphan indication where today there are no approved products," said CEO Renée Aguiar-Lucander. Alport syndrome is a genetic disorder arising from the mutations in the genes that code for type 4 collagen. The type 4…
PR Newswire
27/09/2023

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – September 27 , 2023 – 7 .00PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on September...
Nasdaq GlobeNewswire
27/09/2023

Photocure ASA: Change of Board Composition

The nomination committee has initiated a search for a new Chairperson, and it is expected that the committee will present its recommendations to the annual general meeting in 2024 at the latest. The nomination committee has initiated a search for a new Chairperson, and it is expected that the committee will present its recommendations to the annual general meeting in 2024 at the latest. For further information, please contact: Erik DahlChief Financial Officer Email:ed@photocure...
PR Newswire
27/09/2023

STYLE AGAINST CANCER: New initiative from Children with Cancer UK will raise…

Data from Children with Cancer UK indicates that sadly, cancer is still the leading cause of death in children under 14*. Around 240 children in the UK (aged 0 – 14 years) lose their lives to cancer each year* and 10 families a day receive a cancer diagnosis for their child, teenager, or young person*. Two in three childhood cancer survivors will experience long term side effects because of their cancer, or cancer treatment, including heart failure, reduced mobility, and fertility problems*. ...
PR Newswire
27/09/2023

SCIENTISTS PIONEER DEVELOPMENT OF MULTI-DISEASE RAPID TESTS AS EDX MEDICAL PLC…

These advanced 'point-of-care' tests will be used by health professionals wherever they work, to identify early signs and details of cancer, infections, and cardio-vascular conditions. These advanced 'point-of-care' tests will be used by health professionals wherever they work, to identify early signs and details of cancer, infections, and cardio-vascular conditions. Multiple assays can be combined on a single smartphone-readable device supporting real time clinical decision-making and...
PR Newswire
27/09/2023

Fitness Superstore: Home and commercial gyms in the United Kingdom and Ireland…

REP's award-winning power racks, benches, functional training gyms, and more are already available to order online at Fitness Superstore, and will soon be ready for UK customers to try out and order in their 11 showrooms across the UK. Fitness Superstore, founded in 1994, is the largest supplier of specialist fitness equipment in the UK and is proud to feature the largest fitness equipment showrooms in the UK. REP'saward-winningpower racks, benches, functional training gyms, and more are...
PR Newswire
27/09/2023

Medical Aesthetics Market worth $25.9 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=885 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=885 Browse in-depth TOC on "Medical Aesthetics Market" 253 - Tables 37 - Figures 310 - Pages Medical Aesthetics Market Scope: Facial Aesthetics Product segment to register significant growth rate over the forecast period of 2023-2028. Based on the product, the global Medical...
PR Newswire
27/09/2023

Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in…

The results from the NIPU study will be presented by the Principal Investigator as an oral presentation at the ESMO Congress 2023 in Madrid, Spain, 20-24 October 2023.Oslo, September 27, 2023– Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced today that the results from the UV1 Phase II clinical trial NIPU will be presented at the ESMO Congress 2023 in Madrid, Spain, 20-24 October 2023.The...
Nasdaq GlobeNewswire
27/09/2023

Global Anaesthesia Machines Market poised to expand at an 8.6% CAGR through 2033…

Get a Close Overview of the Anaesthesia Machines Market with our Sample Copy: https://www.futuremarketinsights.com/reports/sample/rep-gb-789 Get a Close Overview of the Anaesthesia Machines Market with our Sample Copy:https://www.futuremarketinsights.com/reports/sample/rep-gb-789 Anesthesiologists can guide primary health care providers in remote areas through anesthesia machines and telemedicine platforms. As a result, the market can be expanded significantly. Anesthesia...
PR Newswire
27/09/2023

Doceree raises $35 million in Series B funding, led by Creaegis with…

Driven solely by the mission to transform healthcare professional (HCP) marketing globally, the funds will enable Doceree to accelerate product development, augment technologies, scale global expansion, and expand team. Driven solely by the mission to transform healthcare professional (HCP) marketing globally, the funds will enable Doceree to accelerate product development, augment technologies, scale global expansion, and expand team. Founded in 2019, Doceree empowers pharmaceutical and...
PR Newswire
27/09/2023
Altri  Comunicati